Novel S1P1 receptor agonists - Part 1: From pyrazoles to thiophenes

Journal of Medicinal Chemistry

Volumn 56, Issue 23, 2013, Pages 9737-9755

  Bolli, Martin H ^a   Müller, Claus ^a   Mathys, Boris ^a   Abele, Stefan ^a   Birker, Magdalena ^a   Bravo, Roberto ^a   Bur, Daniel ^a   Hess, Patrick ^a   Kohl, Christopher ^a   Lehmann, David ^a   Nayler, Oliver ^a   Rey, Markus ^a   Meyer, Solange ^a   Scherz, Michael ^a   Schmidt, Gunther ^a   Steiner, Beat ^a   Treiber, Alexander ^a   Velker, Jörg ^a   Weller, Thomas ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PYRAZOLE DERIVATIVE; SPHINGOSINE 1 PHOSPHATE RECEPTOR ANTAGONIST; SPHINGOSINE DERIVATIVE; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1-PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BRAIN TISSUE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DOG; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HEART RATE; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; DRUG POTENTIATION; DRUG STABILITY; METABOLISM; SYNTHESIS;

ANIMALS; DOGS; DRUG STABILITY; LYMPHOCYTE COUNT; LYSOPHOSPHOLIPIDS; PYRAZOLES; RATS; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 84890479389     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4014373     Document Type: Article

References (85)

1. Kappos, L.; Antel, J.; Comi, G.; Montalban, X.; O'Connor, P.; Polman, C. H.; Haas, T.; Korn, A. A.; Karlsson, G.; Radue, E. W. Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis N. Engl. J. Med. 2006, 355, 1124-1140
2. Kappos, L.; Radue, E.-W.; O'Connor, P.; Polman, C.; Hohlfeld, R.; Calabresi, P.; Selmaj, K.; Agoropoulou, C.; Leyk, M.; Zhang-Auberson, L.; Burtin, P. A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis N. Engl. J. Med. 2010, 362, 387-401
3. Cohen, J. A.; Chun, J. Mechanisms of Fingolimod's Efficacy and Adverse Effects in Multiple Sclerosis Ann. Neurol. 2011, 69, 759-777
4. Brinkmann, V.; Davis, M. D.; Heise, C. E.; Albert, R.; Cottens, S.; Hof, R.; Bruns, C.; Prieschl, E.; Baumruker, T.; Hiestand, P.; Foster, C. A.; Zollinger, M.; Lynch, K. R. The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors J. Biol. Chem. 2002, 277, 21453-21457
5. Mandala, S.; Hajdu, R.; Bergstrom, J.; Quackenbush, E.; Xie, J.; Milligan, J.; Thornton, R.; Shei, G.-J.; Card, D.; Keohane, C. A.; Rosenbach, M.; Hale, J.; Lynch, C. L.; Rupprecht, K.; Parsons, W.; Rosen, H. Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists Science 2002, 296, 346-349
6. Billich, A.; Bornancin, F.; Dévay, P.; Mechtcheriakova, D.; Urtz, N.; Baumruker, T. Phosphorylation of the Immunomodulatory Drug FTY720 by Sphingosine Kinases J. Biol. Chem. 2003, 278, 47408-47415
7. 3 Receptors and Smad-Independent Signaling J. Biol. Chem. 2013, 288, 14839-14851
8. 1, on T-cells Controls Thymic Emigration J. Biol. Chem. 2004, 279, 15396-15401
9. Matloubian, M.; Lo, C. G.; Cinamon, G.; Lesneski, M. J.; Xu, Y.; Brinkmann, V.; Allende, M. L.; Proia, R. L.; Cyster, J. G. Lymphocyte Egress from Thymus and Peripheral Lymphoid Organs Is Dependent on S1P Receptor 1 Nature 2004, 427, 355-360
10. Hale, J. J.; Neway, W.; Mills, S. G.; Hajdu, R.; Keohane, C. A.; Rosenbach, M.; Milligan, J.; Shei, G.-J.; Chrebet, G.; Bergstrom, J.; Card, D.; Koo, G. C.; Koprak, S. L.; Jackson, J. J.; Rosen, H.; Mandala, S. Potent S1P Receptor Agonists Replicate the Pharmacologic Actions of the Novel Immune Modulator FTY720 Bioorg. Med. Chem. Lett. 2004, 14, 3351-3355
11. Jo, E.; Sanna, M. G.; Gonzalez-Cabrera, P. J.; Thangada, S.; Tigyi, G.; Osborne, D. A.; Hla, T.; Parrill, A. L.; Rosen, H. S1P1-Selective In Vivo-Active Agonists from High-Throughput Screening: Off-the-Shelf Chemical Probes of Receptor Interactions, Signaling, and Fate Chem. Biol. 2005, 12, 703-715
12. McVerry, B. J.; Garcia, J. G. N. In vitro and in Vivo Modulation of Vascular Barrier Integrity by Sphingosine 1-Phosphate: Mechanistic Insights Cell. Signalling 2005, 17, 131-139
13. Wei, S. H.; Rosen, H.; Matheu, M. P.; Sanna, M. G.; Wang, S.-K.; Jo, E.; Wong, C.-H.; Parker, I.; Cahalan, M. D. Sphingosine 1-Phosphate Type 1 Receptor Agonism Inhibits Transendothelial Migration of Medullary T Cells to Lymphatic Sinuses Nat. Immunol. 2005, 6, 1228-1235
14. Rosen, H.; Alfonso, C.; Surh, C. D.; McHeyzer-Williams, M. G. Rapid Induction of Medullary Thymocyte Phenotypic Maturation and Egress Inhibition by Nanomolar Sphingosine 1-Phosphate Receptor Agonist Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 10907-10912
15. Sanna, M. G.; Wang, S.-K.; Gonzalez-Cabrera, P. J.; Don, A.; Marsolais, D.; Matheu, M. P.; Wei, S. H.; Parker, I.; Jo, E.; Cheng, W.-C.; Cahalan, M. D.; Wong, C.-H.; Rosen, H. Enhancement of Capillary Leakage and Restoration of Lymphocyte Egress by a Chiral S1P1 Antagonist in Vivo Nat. Chem. Biol. 2006, 8, 434-441
16. Marsolais, D.; Rosen, H. Chemical Modulators of Sphingosine-1-phosphate Receptors as Barrier-Oriented Therapeutic Molecules Nat. Rev. Drug Discovery 2009, 8, 297-307
17. Hla, T.; Venkataraman, K.; Michaud, J. The Vascular S1P Gradient-Cellular Sources and Biological Significance Biochim. Biophys. Acta 2008, 1781, 477-482
18. 1 G Protein-Coupled Receptor J. Immunol. 2003, 171, 3500-3507
19. Schwab, S. R.; Cyster, J. G. Finding a Way Out: Lymphocyte Egress from Lymphoid Organs Nat. Immunol. 2007, 8, 1295-1301
20. Pappu, R.; Schwab, S. R.; Cornelissen, I.; Pereira, J. P.; Regard, J. B.; Xu, Y.; Camerer, E.; Zheng, Y.-W.; Huang, Y.; Cyster, J. G.; Coughlin, S. R. Promotion of Lymphocyte Egress into Blood and Lymph by Distinct Sources of Sphingosine-1-Phosphate Science 2007, 316, 295-298
21. Sensken, S.-C.; Nagarajan, M.; Bode, C.; Graeler, M. H. Local Inactivation of Spingosine 1-Phosphate in Lymph Nodes Induces Lymphopenia J. Immunol. 2011, 186, 3432-3440
22. Berst, F.; Grosche, P.; Janser, P.; Zecri, F.; Bollbuck, B. N-Biaryl (Hetero) Arylsulphonamide Derivatives Useful in the Treatment of Diseases Mediated by Lymphocyte Interactions. WO2008028937 A1, March 13, 2008.
23. Tarrasón, G.; Aulí, M.; Mustafa, S.; Dolgachev, V.; Domènech, M. T.; Prats, N.; Domínguez, M.; López, R.; Auilar, N.; Calbet, M.; Pont, M.; Milligan, G.; Kunkel, S. L.; Godessart, N. The Sphingosine-1-phosphate Receptor-1 Antagonist, W146, Causes Early and Short-Lasting Peripheral Blood Lymphophenia in Mice Int. Immunopharmacol. 2011, 11, 1773-1779
24. 1 Antagonist Structurally Unrelated to S1P Biochim. Biophys. Acta 2012, 1821, 600-606
25. 1 Antagonist with Immunomodulatory Activities J. Immunol. 2012, 188, 206-215
26. Foster, C. A.; Howard, L. M.; Schweitzer, A.; Persohn, E.; Hiestand, P. C.; Balatoni, B.; Reuschel, R.; Beerli, C.; Schwartz, M.; Billich, A. Brain Penetration of the Oral Immunomodulatory Drug FTY720 and Its Phosphorylation in the Central Nervous System during Experimental Autoimmune Encephalomyelitis: Consequences for Mode of Action in Multiple Sclerosis J. Pharmcol. Exp. Ther. 2007, 323, 469-476
27. Balatoni, B.; Storch, M. K.; Swoboda, E.-M.; Schönborn, V.; Koziel, A.; Lambrou, G. N.; Hiestand, P. C.; Weissert, R.; Foster, C. A. FTY720 Sustains and Restores Neuronal Function in the DA Rat Model of MOG-Induced Experimental Autoimmune Encephalomyelitis Brain Res. Bull. 2007, 74, 307-316
28. Dev, K. K.; Mullershausen, F.; Mattes, H.; Kuhn, R. R.; Bilbe, G.; Hoyer, D.; Mir, A. Brain Sphingosine-1-phosphate Receptors: Implication for FTY720 in the Treatment of Multiple Sclerosis Pharmacol. Ther. 2008, 117, 77-93
29. Miron, V. E.; Schubart, A.; Antel, J. P. Central Nervous System-Directed Effects of FTY720 (Fingolimod) J. Neurol. Sci. 2008, 274, 13-17
30. Miron, V. E.; Hall, J. A.; Kennedy, T. E.; Soliven, B.; Antel, J. P. Cyclical and Dose-Dependent Responses of Adult Human Mature Oligodendrocytes to Fingolimod Am. J. Pathol. 2008, 173, 1143-1152
31. Chun, J.; Hartung, H.-P. Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis Clin. Neuropharmacol. 2010, 33, 91-101
32. Lee, C. W.; Choi, J. W.; Chun, J. Neurological S1P Signalling as an Emerging Mechanism of Action of Oral FTY720 (Fingolimod) in Multiple Sclerosis Arch. Pharm. Res. 2010, 33, 1567-1574
33. Kipp, M.; Amor, S. FTY720 on the Way from the Base Camp to the Summit of the Mountain: Relevance for Remyelination Mult. Scler. J. 2012, 18, 258-263
34. Awad, A. S.; Rouse, M. D.; Khutsishvili, K.; Huang, L.; Bolton, W. K.; Lynch, K. R.; Okusa, M. D. Chronic Sphingosine 1-Phosphate 1 Receptor Activation Attenuates Early-Stage Diabetic Nephropathy Independent of Lymphocytes Kidney Int. 2011, 79, 1090-1098
35. Miron, V. E.; Ludwin, S. K.; Darlington, P. J.; Jarjour, A. A.; Soliven, B.; Kennedy, T. E.; Antel, J. P. Fingolimod (FTY720) Enhances Remyelination Following Demyelination of Organotypic Cerebellar Slices Am. J. Pathol. 2010, 176, 2682-2694
36. Mattes, H.; Dev, K. K.; Bouhelal, R.; Barske, C.; Gasparini, F.; Guerini, D.; Mir, A. K.; Orain, D.; Osinde, M.; Picard, A.; Dubois, C.; Tasdelen, E.; Haessig, S. Design and Synthesis of Selective and Potent Orally Active S1P5 Agonists ChemMedChem 2010, 5, 1693-1696
37. 1) Modulation Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 751-756
38. 3 Enhances the Acute Cardiovascular Tolerability of 3-(N-Benzyl)aminopropylphosphonic Acid S1P Receptor Agonists Bioorg. Med. Chem. Lett. 2004, 14, 3501-3505
39. Forrest, M.; Sun, S.-Y.; Hajdu, R.; Bergstrom, J.; Card, D.; Doherty, G.; Hale, J.; Keohane, C.; Meyers, C.; Milligan, J.; Mills, S.; Nomura, N.; Rosen, H.; Rosenbach, M.; Shei, G.-J.; Singer, I. I.; Tian, M.; West, S.; White, V.; Xie, J.; Proia, R. L.; Mandala, S. Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes J. Pharmacol. Exp. Ther. 2004, 309, 758-768
40. 3, Respectively, Regulate Lymphocyte Recirculation and Heart Rate J. Biol. Chem. 2004, 279, 13839-13848
41. Salomone, S.; Potts, E. M.; Tyndall, S.; Ip, P. C.; Chun, J.; Brinkmann, V.; Waeber, C. Analysis of Sphingosine 1-Phosphate Receptors Involved in Constriction of Isolated Cerebral Arteries with Receptor Null Mice and Pharmacological Tools Br. J. Pharmacol. 2008, 153, 140-147
42. 3 Receptor Antagonist Mol. Pharmacol. 2010, 77, 704-713
43. Saha, A. K.; Yu, X.; Lin, J.; Lobera, M.; Shardendu, A.; Chereku, S.; Schutz, N.; Segal, D.; Marantz, Y.; McCauley, D.; Middleton, S.; Siu, J.; Bürli, R. W.; Buys, J.; Horner, M.; Salyers, K.; Schrag, M.; Vargas, H. M.; Xu, Y.; McElvain, M.; Xu, H. Benzofuran Derivatives as Potent, Orally Active S1P1 Receptor Agonists: A Preclinical Lead Molecule for MS ACS Med. Chem. Lett. 2011, 2, 97-101
44. Lucke, S.; Levkau, B. Endothelial Functions of Sphingosine-1-phosphate Cell. Physiol. Biochem. 2010, 26, 87-96
45. Fryer, R. M.; Muthukumarana, A.; Harrison, P. C.; Nodop Mazurek, S.; Chen, R. R.; Harrington, K. E.; Dinallo, R. M.; Horan, J. C.; Patnaude, L.; Modis, L. K.; Reinhart, G. A. The Clinically-Tested S1P Receptor Agonists, FTY720 and BAF312, Demonstrate Subtype-Specific Bradycardia (S1P(1)) and Hypertension (S1P(3)) in Rat PLoS One 2012, 7, e52985
46. 3 Receptor-Induced Reorganization of Epithelial Tight Junctions Compromises Lung Barrier Integrity and Is Potentiated by TNF Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 9270-9275
47. 1 Agonists with Reduced Effect on Heart Rate J. Med. Chem. 2010, 53, 3154-3168
48. Pan, S.; Gray, N.; Gao, W.; Mi, Y.; Fan, Y.; Wang, X.; Tuntland, T.; Che, J.; Lefebvre, S.; Chen, Y.; Chu, A.; Hinterding, K.; Gardin, A.; End, P.; Heining, P.; Bruns, C.; Cooke, N. G.; Nuesslein-Hildesheim, B. Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator ACS Med. Chem. Lett. 2013, 4, 333-337
49. Brinkmann, V. FTY720 (Fingolimod) in Multiple Sclerosis: Therapeutic Effects in the Immune and Central Nervous System Br. J. Pharmacol. 2009, 158, 1173-1182
50. Brossard, P.; Hofmann, S.; Cavallaro, M.; Halabi, A.; Dingemanse, J. Entry-into-Humans Study with ACT-128800, a Selective S1P1 Receptor Agonist: Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics. Clin. Pharmcol. Ther. 2009, S63-S64, PII-87; Annual Meeting of the American Society for Clinical Pharmacology & Therapeutics, March 18-21, 2009, Washington DC, USA; ASCPT: Alexandria, VA.
51. Gergely, P.; Wallström, E.; Nuesslein-Hildesheim, B.; Bruns, C.; Zécri, F. J.; Cooke, N. G.; Traebert, M.; Tuntland, T.; Rosenberg, M.; Saltzman, M. Phase I Study with the Selective S1P1/S1P5 Receptor Modulator BAF312 Indicates That S1P1 Rather Than S1P3 Mediates Transient Heart Rate Reduction in Humans. 25th Congress of the European Committe for Treatment and Research in Multiple Sclerosis (ECTRIMS), Sept 9-12, 2009, Düsseldorf, Germany; p P437.
52. Wallström, E.; Gergely, P.; Nuesslein-Hildesheim, B.; Zécri, F. J.; Cooke, N. G.; Bruns, C.; Luttringer, O.; Sing, T.; Groenewegen, A.; Rosenberg, M.; Saltzman, M. BAF312, a Selective S1P1/S1P5 Receptor Modulator, Effectively Reduces Absolute Lymphocyte Counts in Human Volunteers and Demonstrates the Relevance of S1P1 in Mediating a Transient Heart Rate Reduction. In 62nd Annual Meeting of the American Academy of Neurology, Toronto, Ontario, Canada, 2010; p PO5.052.
53. Gergely, P.; Nuesslein-Hildesheim, B.; Guerini, D.; Brinkmann, V.; Traebert, M.; Bruns, C.; Pan, S.; Gray, N. S.; Hinterding, K.; Cooke, N. G.; Groenewegen, A.; Vitaliti, A.; Sing, T.; Luttringer, O.; Yang, J.; Gardin, A.; Wang, N.; Crumb, W. J. J.; Saltzmann, M.; Rosenberg, M.; Wallström, E. The Selective S1P Receptor Modulator BAF312 Redirects Lymphocyte Distribution and Has Species-Specific Effects on Heart Rate: Translation from Preclinical to Clinical Studies Br. J. Pharmacol. 2012, 167, 1035-1047
54. Brossard, P.; Derendorf, H.; Xu, J.; Maatouk, H.; Halabi, A.; Dingemanse, J. Pharmacokinetics and Pharmacodynamics of Ponesimod, a Selective S1P Receptor Modulator, in the First-in-Human Study. Br. J. Clin. Pharmacol. [Online early access]. DOI 10.1111/bcp.12129. Published Online: April 18, 2013. http://onlinelibrary.wiley.com/doi/10.1111/bcp.12129/abstract;jsessionid= BB7009BA3B1862F516180A38B14839B0.f03t03
55. Popov, S. A.; Denisov, A. Y.; Gatilov, Y. V.; Bagryanskaya, I. Y.; Tkachev, A. V. Synthesis of New Chiral Heterocycles of the Pyrazole and 2-Isoxazoline Types Form (+)-3-Carene Tetrahedron: Asymmetry 1994, 5, 479-489
56. Popov, S. A.; Tkachev, A. V. Synthesis of 2-Alkyl and 2-Aryl Pyrimidines from β-Chlorovinyl Ketones of Cyclopentanone Type Synth. Commun. 2001, 31, 233-243
57. Gajcy, K.; Librowski, T.; Lochynski, S. Concise Synthesis fo Non-protein Amino Acid from Natural Product via Schmidt Reaction Lett. Org. Chem. 2009, 6, 186-188
58. Gajcy, K.; Pekala, J.; Frackowiak-Wojtasek, B.; Librowski, T.; Lochynski, S. Stereochemistry of Terpene Derivatives. Part 7: Novel Rigidified Amino Acids from (+)-3-Carene Designed as Chiral GABA Analogues Tetrahedron: Asymmetry 2010, 21, 2015-2020
59. Appel, R. Tertiary Phosphane/Tetrachloromethane, a Versatile Reagent for Chlorination, Dehydration, and P-N Linkage Angew. Chem., Int. Ed. 1975, 14, 801-811
60. Popov, S. A.; Tkachev, A. V. New Chiral Agents for Resolution of Racemic cis -Permethric and cis -Z-Cyhalothric Acids Tetrahedron: Asymmetry 1995, 6, 1013-1018
61. Walkowicz, M.; Lochynski, S.; Walkowicz, C. Stereochemistry of Bicyclo[3.1.0]hexane Derivatives. Part XII. Optically Active 6,6-Dimethylbicyclo[3.1.0]hexan-2-ols Pol. J. Chem. 1981, 55, 135-140
62. Malkov, A. V.; Pernazza, D.; Bell, M.; Bella, M.; Massa, A.; Teply, F.; Meghani, P.; Kocovsky, P. Synthesis of New Chiral 2,2′-Bipyridine Ligands and Their Application in Copper-Catalyzed Asymmetric Allylic Oxidation and Cyclopropanation J. Org. Chem. 2003, 68, 4727-4742
63. Boatman, D. P.; Schrader, T. O.; Semple, G.; Skinner, P. J.; Jung, J.-K. Fused Pyrazole Derivatives and Methods of Treatment of Metabolic-Related Disorders Thereof. WO2006069242, Jun 29, 2006.
64. Boatman, P. D.; Schrader, T. O.; Kasem, M.; Johnson, B. R.; Skinner, P. J.; Jung, J.-K.; Xu, J.; Cherrier, M. C.; Webb, P. J.; Semple, G.; Sage, C. R.; Knudsen, J.; Chen, R.; Taggart, A. K.; Carballo-Jane, E.; Richman, J. G. Potent Tricyclic Pyrazole Tetrazole Agonists of the Nicotinic Acid Receptor (GPR109a) Bioorg. Med. Chem. Lett. 2010, 20, 2797-2800
65. Paine, J. B.; Brough, J. R.; Buller, K. K.; Erikson, E. E. Regioselectivity of Pyrrole Synthesis from Diethyl Aminomalonate and 1,3-Diketones: Further Observations J. Org. Chem. 1987, 52, 3986-3993
66. Bolli, M.; Bur, D.; Clozel, M.; Fischli, W.; Lehmann, D.; Mathys, B.; Mueller, C.; Nayler, O.; Scherz, M.; Weller, T. 4-Carbonyl Substituted 1,1,2-Trimethyl-1A,4,5,5A-Tetrahydro-1H-4-Aza-Cyclopropa[a]pentalene Derivatives as Agonists for the G-Protein Coupled Receptor S1P1/EDG1 and Immunsuppressant Agents. WO2005123677, Dec 29, 2005.
67. Alberola, A.; Andres, J. M.; Gonzalez, A.; Pedrosa, R.; Vicente, M. The Reaction of β-Aminoenones with α-Amino Derivatives. Synthesis of 2-Functionalized Pyrroles Heterocycles 1990, 31, 1049-1058
68. Hombrecher, H. K.; Horter, G. Synthesis of Pyrroles via Ethyl N-(3-Oxo-1-alkenyl)glycinates Synthesis 1990, 1990, 389-391
69. Alberola, A.; Andres, J. M.; Gonzalez, A.; Pedrosa, R.; Pradanos, P. Regioselective Synthesis of 2-Functionalized Thiophenes by Condensation of α-Mercapto Compounds with β-Amino Enone Derivatives Synth. Commun. 1990, 20, 2537-2547
70. Bolli, M.; Bur, D.; Clozel, M.; Fischli, W.; Lehmann, D.; Mathys, B.; Mueller, C.; Nayler, O.; Scherz, M.; Weller, T. 1, 1A, 5, 5A-Tetrahydro-3-thia- cycloprop[a] pentalenes: Tricyclic Thiophene Derivatives as S1P1/EDG1 Receptor Agonists. WO2006010544, Feb 2, 2006.
71. Bolli, M.; Lehmann, D.; Mathys, B.; Mueller, C.; Nayler, O.; Velker, J.; Weller, T. Novel Thiophene Derivatives. WO2006100635, Sep 28, 2006.
72. Diana, G. D.; Rudewicz, P.; Pevear, D. C.; Nitz, T. J.; Aldous, S. C.; Aldous, D. J.; Robinson, D. T.; Draper, R.; Dutko, F. J.; Aldi, C.; Gendron, G.; Oglesby, R. C.; Volkots, D. L.; Reuman, M.; Bailey, R. R.; Czerniak, R.; Block, T.; Roland, R.; Oppermann, J. Picornavirus Inhibitors: Trifluoromethyl Substitution Provides a Global Protective Effect agains Hepatic Metabolism J. Med. Chem. 1995, 38, 1355-1371
73. Bolli, M.; Lehmann, D.; Mathys, B.; Mueller, C.; Nayler, O.; Velker, J.; Weller, T. Novel Thiophene Derivatives as Sphingosine-1-phosphate Receptor Agonists. WO2006100633, Sep 28, 2006.
74. Rasmussen, P. B.; Pedersen, U.; Thomsen, I.; Yde, B.; Lawesson, S.-O. Studies on Organophosphorus Compounds XLIX. An Improved Method for the Preparation of 2,5-Disubstituted 1,3,4-Thiadiazoles and 1,3,4-Thiadiazole-2(3H)- Thiones Bull. Soc. Chim. Fr. 1985, 1985, II/62-II/65
75. Kiryanov, A. A.; Sampson, P.; Seed, A. J. Synthesis of 2-Alkoxy-Substituted Thiophenes, 1,3-Thiazoles, and Related S-Heterocycles via Lawesson's Reagent-Mediated Cyclization under Microwave Irradiation: Applications for Liquid Crystal Synthesis J. Org. Chem. 2001, 66, 7925-7929
76. Brain, C. T.; Paul, J. M. Rapid Synthesis of Oxazoles under Microwave Conditions Synlett 1999, 1999, 1642-1644
77. Holub, J. M.; O'Toole-Colin, K.; Getzel, A.; Argenti, A.; Evans, M. A.; Smith, D. C.; Dalglish, G. A.; Rifat, S.; Wilson, D. L.; Taylor, B. M.; Miott, U.; Glersaye, J.; Lam, K. S.; McCranor, B. J.; Berkowitz, J. D.; Miller, R. B.; Lukens, J. R.; Krumpe, K.; Gupton, J. T.; Burnham, B. S. Lipid-Lower Effects of Ethyl 2-Phenacyl-3-aryl-1H-pyrrole-4-carboxylates in Rodents Molecules 2004, 2004, 135-157
78. Hedegaard, B.; Mortensen, J. Z.; Lawesson, S.-O. Tetrahedron 1971, 27, 3853-3859
79. 1) Receptor Agonists Bioorg. Med. Chem. Lett. 2010, 20, 35-37
80. Bolli, M. H.; Abele, S.; Binkert, C.; Bravo, R.; Buchmann, S.; Bur, D.; Gatfield, J.; Hess, P.; Kohl, C.; Mangold, C.; Mathys, B.; Menyhart, K.; Müller, C.; Nayler, O.; Scherz, M.; Schmidt, G.; Sippel, V.; Steiner, B.; Strasser, D.; Treiber, A.; Weller, T. 2-Imino-thiazolidin-4-one Derivatives as Potent, Orally Active S1P1 Receptor Agonists J. Med. Chem. 2010, 53, 4198-4211
81. Bolli, M. H.; Velker, J.; Müller, C.; Mathys, B.; Birker, M.; Bravo, R.; Bur, D.; de Kanter, R.; Hess, P.; Kohl, C.; Lehmann, D.; Meyer, S.; Nayler, O.; Rey, M.; Scherz, M.; Steiner, B., unpublished work.
82. Brockway, B. P.; Mills, P. A.; Azar, S. H. A New Method for Continuous Chronic Measurement and Recording of Blood Pressure, Heart Rate and Activity in the Rat via Radio-Telemetry Clin. Exp. Hypertens., Part A 1991, A13, 885-895
83. Guiol, C.; Ledoussal, C.; Surgé, J.-M. A Radiotelemetry System for Chronic Measurement of Blood Pressure and Heart Rate in the Unrestrained Rat Validation of the Method J. Pharmcol. Toxicol. Methods 1992, 28, 99-105
84. Hess, P.; Clozel, M.; Clozel, J.-P. Telemetry Monitoring of Pulmonary Arterial Pressure in Freely Moving Rats J. Appl. Physiol. 1996, 81, 1027-1032
85. Grimont, J.; Le Goff, F.; Bourquin, G.; Silva, J. Quality Assessment and Concentration Determination of Actelion's Compound Solutions by Automated LCMS and Quantitative NMR. MipTec-The Leading European Event for Drug Discovery, Basel, Switzerland, Sept 20-24, 2010.